profit from every $100 of sales.
$0$100
ArriVent BioPharma
$14.16+3.81% today
-29.9% in 1 year
1-year low $12.231-year high $34.74
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What ArriVent BioPharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$166 million of profit last year.
SalesProfit
ArriVent BioPharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| ArriVent BioPharma | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads ArriVent BioPharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -37 | -75 | -94 | -178 | |
| -37 | -75 | -94 | -178 | |
| -37 | -69 | -80 | -166 | |
| -1.15 | -2.17 | -2.56 | -4.32 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 183 | 163 | 275 | 333 |
| Cash | 163 | 150 | 74 | 46 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 268 | 316 | 17 | 26 |
| -85 | -153 | 258 | 307 | |
| 32 | 32 | 31 | 38 | |
| – | – | -28.9% | -45.6% | |
| 43.4% | 45.3% | -31.2% | -54.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -44 | -56 | -70 | -161 | |
| – | – | – | – | |
| -44 | -56 | -70 | -161 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 1 | 3 | 13 |
Valuation
- –
- –
- –
- 3.7×
- –
- –
- –
- -23.0%
- -23.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -57.8%
- -55.5%
- -62.5%
- -49.9%
- -57.8%
- –
Growth
- –
- –
- −128.7%
- –
- +134.3%
Financial health
- 0.3×
- 0.00
- 0.0%
- –
- 12.83
- 12.83
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 5%of 948
Bottom 21%of 871
Bottom 3%of 985
What analysts expect
- Average price target
- $44.00
- Range
- $43.00 – $45.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.96 | -0.88 | −9.1% |
| Mar 5, 2026 | -0.78 | -0.87 | +10.3% |
| Nov 10, 2025 | -0.83 | -0.78 | −6.4% |
| Aug 11, 2025 | -0.90 | -0.70 | −28.6% |
| May 12, 2025 | -1.90 | -0.66 | −187.9% |
| Mar 3, 2025 | -0.60 | -0.78 | +23.1% |
| Nov 14, 2024 | -0.61 | -0.82 | +25.6% |
| Aug 14, 2024 | -0.65 | -0.65 | +0.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
40No pass
Philip Fisher
41No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
38No pass
Terry Smith
34No pass
Questions about ArriVent BioPharma
Is ArriVent BioPharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the ArriVent BioPharma AI analysis
What does ArriVent BioPharma do?
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It is in Biotechnology.
Does ArriVent BioPharma pay a dividend?
No. ArriVent BioPharma does not pay a dividend at the moment.
Is ArriVent BioPharma stock halal?
Questionable. ArriVent BioPharma sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has ArriVent BioPharma stock done over the past year?
Down 29.9% over the past twelve months, to $14.16. It traded between $12.23 and $34.74 and is 59.2% below its high.
Who are ArriVent BioPharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with ArriVent BioPharma's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.